Vanderbilt-Ingram Cancer Center

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center [...]

A breast cancer patient who has enrolled in two clinical research trials at Vanderbilt-Ingram Cancer Center was the only presenter to receive a standing ovation during a recent Stand Up To Cancer (SU2C) news briefing at the American Association for Cancer Research (AACR) annual meeting in Chicago. Jeanette Daniel, 51, a metastatic breast cancer patient, [...]

Pelayo Correa, M.D., professor of Pathology, Microbiology and Immunulogy, has been recognized by the American Association for Cancer Research (AACR) and its Minorities in Cancer Research membership group with the Jane Cooke Wright Lectureship. Correa holds the Anne Potter Wilson chair in cancer research in the Division of Gastroenterology, Hepatology and Nutrition. The AACR-MICR-Jane Cooke [...]

Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry at Vanderbilt, will receive the 2012 AACR Award for Outstanding Achievement in Chemistry in Cancer Research. Fesik, who holds the Orrin H. Ingram II chair in cancer research, will receive the special recognition during the American Association for Cancer Research (AACR) Annual Meeting in Chicago March [...]

Breast cancer researchers gathered earlier this month for the annual San Antonio Breast Cancer Symposium. In this video interview with the American Association for Cancer Research, you will hear Vanderbilt-Ingram Cancer Center’s Dr. Carlos Arteaga discuss translational insights for clinical research and practice at the meeting, as well as his exciting research in women’s cancer as part of a Stand Up To Cancer “Dream Team.”

William Pao, M.D., Ph.D., associate professor of Medicine, Vanderbilt-Ingram Cancer Center, has been awarded a grant from Stand Up to Cancer (SU2C) to study molecules that could speed up the search for new cancer drugs and targets. He is one of 13 young cancer investigators to earn a grant from SU2C.